PFESeagen, a wholly owned subsidiary of PfizerRunning, no new patients
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
Urothelial Carcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 412 (final count)
- Started
- Sep 22, 2023
- Main results expected
- Jan 29, 2027
- Fully finished
- Apr 30, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by blinded independent central review (BICR)
Measured over: Approximately 3 years
Overall survival (OS)
Measured over: Approximately 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05911295 · record last updated 2026-07-22 · checked 2026-11-09 15:36 UTC